Home > Companies > Gold Biotechnology, Inc.

Gold Biotechnology, Inc.

goldbio.com

Gold Biotechnology shares a vision with every researcher: Each facet of life science research will introduce us to a future of impactful discovery and learning, benefitting the entire world. And our vision will materialize sooner if a researcher’s passion is not sullied by worry over the quality of their reagents, especially the cost for quality. This is why we’re here! We believe in a future of change and prosperity, and we want to help you get there by being a resource for high-quality products at exceptional prices. By providing our customers with only the best chemicals possible, tested in GoldBio labs to assure our own quality specifications are met, you can be sure your research will go off without a hitch.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

National Medtech & Biotech Summit 2024

Conference

Pharma 2024

Conference

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

Related News

Pharmacy Market

VIRPAX PHARMACEUTICALS RECAPS MILESTONES AND HIGHLIGHTS PRODUCT PORTFOLIO

Virpax® Pharmaceuticals, Inc. | December 29, 2021

Virpax® Pharmaceuticals, Inc. "Company" achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I believe that Virpax has made significant progress this past year toward our stated goalsThese accomplishments include accelerated development of our existing product candidates, broadening our pipeline of product candidates, and utilizing grants where appropriate. We recently...

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Research, PHARMA TECH

OM1 RELEASES ANALYTIC REPORTS, UNCOVERING MEDICATION DISCONTINUATION IN PATIENTS

OM1 | February 06, 2023

OM1, a leading real-world data, results, and technology firm focused on chronic diseases, recently announced the release of its Reasons for Discontinuation (RfD) Analytic Reports. Utilizing the OM1 Real-World Data CloudTM, Immunology Real-World Data Network, and proprietary artificial intelligence (AI) technology, the RfD reports provide difficult-to-obtain, extremely valuable discontinuation trends for cDMARDs, bDMARDs, and tsDMARDs in primary dermatologic and rheumatologic conditions. Read More

Business Insights

INDIVIOR TO ACQUIRE OPIANT PHARMACEUTICALS

Indivior | November 21, 2022

Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch. The transaction has been unanimously approved by the boards of di...

Pharmacy Market